How does PHAT's PS Ratio compare to its peers?

PHAT is good value based on its Price-To-Sales Ratio (22.7x) compared to the peer average (23.8x).

How does PHAT's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

PHAT is expensive based on its Price-To-Sales Ratio (22.7x) compared to the US Pharmaceuticals industry average (2.5x).

What is PHAT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHAT is expensive based on its Price-To-Sales Ratio (22.7x) compared to the estimated Fair Price-To-Sales Ratio (21.1x).

What is the Fair Price of PHAT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

PHAT ($8.73) is trading below our estimate of [[fair value]] ($118.1)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Phathom Pharmaceuticals (Nasdaq:PHAT) - Stock Price, News & Analysis

PHAT Stock Overview

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. More details

PHAT fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 92.6% below our estimate of its fair value

Revenue is forecast to grow 53.17% per year

Risk Analysis

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market

Shareholders have been diluted in the past year

Phathom Pharmaceuticals, Inc. Competitors

CorMedix

NasdaqGM:CRMD

US$671.7m

Avadel Pharmaceuticals

NasdaqGM:AVDL

US$1.0b

BioStem Technologies

OTCPK:BSEM

US$211.1m

scPharmaceuticals

NasdaqGS:SCPH

US$176.1m

Price History & Performance

Summary of all time highs, changes and price drops for Phathom Pharmaceuticals
Historical stock prices
Current Share Price	US$8.73
52 Week High	US$19.71
52 Week Low	US$6.07
Beta	0.72
11 Month Change	-43.75%
3 Month Change	-31.85%
1 Year Change	24.89%
33 Year Change	-58.05%
5 Year Change	-65.08%
Change since IPO	-64.51%

Following Up On Phathom Pharmaceuticals

Sep 03

Recent updates

Following Up On Phathom Pharmaceuticals

Sep 03

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Jun 26

Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorder

Nov 30

Shareholder Returns

	PHAT	US Pharmaceuticals	US Market
7D	-10.5%	-3.8%	-1.0%
1Y	24.9%	9.8%	30.3%

Return vs Industry: PHAT exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.

Return vs Market: PHAT underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is PHAT's price volatile compared to industry and market?
PHAT volatility
PHAT Average Weekly Movement	13.7%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PHAT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PHAT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2018	452	Terrie Curran	www.phathompharma.com

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals, Inc. Fundamentals Summary

How do Phathom Pharmaceuticals's earnings and revenue compare to its market cap?
PHAT fundamental statistics
Market cap	US$640.70m
Earnings (TTM)	-US$339.44m
Revenue (TTM)	US$26.27m

22.7x

P/S Ratio

-1.8x

P/E Ratio

Is PHAT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHAT income statement (TTM)
Revenue	US$26.27m
Cost of Revenue	US$4.33m
Gross Profit	US$21.95m
Other Expenses	US$361.39m
Earnings	-US$339.44m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.96
Gross Margin	83.54%
Net Profit Margin	-1,292.14%
Debt/Equity Ratio	-277.0%

How did PHAT perform over the long term?

See historical performance and comparison

PHAT Stock Overview

Rewards

Risk Analysis

Phathom Pharmaceuticals, Inc. Competitors

NasdaqGM:CRMD

US$671.7m

NasdaqGM:AVDL

US$1.0b

OTCPK:BSEM

US$211.1m

NasdaqGS:SCPH

US$176.1m

Price History & Performance

Recent News & Updates

Consensus revenue estimates increase by 16%

New minor risk - Share price stability

Price target increased by 9.6% to US$24.43

Phathom Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Following Up On Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $129.999992 million.

Recent updates

Consensus revenue estimates increase by 16%

New minor risk - Share price stability

Price target increased by 9.6% to US$24.43

Phathom Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Following Up On Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $129.999992 million.

Phathom Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $129.999992 million.

Consensus EPS estimates fall by 14%, revenue upgraded

New minor risk - Profitability

Phathom Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

President recently sold US$397k worth of stock

Phathom Pharmaceuticals Announces FDA Approval of Vquezna®? (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GermanyD in Adults

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Consensus EPS estimates fall by 12%

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

President recently sold US$154k worth of stock

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

New minor risk - Profitability

Forecast to breakeven in 2026

Phathom Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Phathom Pharmaceuticals Announces Voquezna® (Vonoprazan) Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Consensus revenue estimates decrease by 45%

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

New minor risk - Share price stability

Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? (Vonoprazan) Tablets

New major risk - Negative shareholders equity

Independent Director recently bought US$59k worth of stock

Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany

Consensus EPS estimates upgraded to US$3.83 loss, revenue downgraded

New major risk - Financial position

Price target increased by 14% to US$18.67

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $130.71875 million.

Consensus EPS estimates upgraded to US$4.52 loss

President recently bought US$101k worth of stock

Consensus revenue estimates decrease by 66%, EPS upgraded

Price target decreased by 12% to US$18.20

Phathom Pharmaceuticals, Inc. Approves in the U.S. for the Treatment of H. Pylori Infection, and Its Pending New Drug Application (NDA) for Vonoprazan for the Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Phathom Pharmaceuticals, Inc. Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

Price target decreased to US$26.20

High number of new directors

Phathom Pharmaceuticals, Inc. Completes Patient Enrollment in Its Phalcon-Nerd Daily Dosing Phase 3 Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

Phathom Pharmaceuticals, Inc Appoints James Topper to its Board of Directors

Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Consensus forecasts updated

The Prognosis For Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of Vonoprazan NDA for Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. Presents Data on Novel Potassium-Competitive Acid Blocker Vonoprazan from Range of Studies at Digestive Disease Week 2022

Price target decreased to US$42.80

Co-Founder & COO recently bought US$163k worth of stock

Price target decreased to US$46.20

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

High number of new and inexperienced directors

Phathom Pharmaceuticals, Inc. Appoints Frank Karbe to its Board of Directors

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)